Beverly is a pediatric pharmacist by training and has spent over 20 years working in biotechnology, holding diverse Medical Affairs roles across Europe, the United States, Asia Pacific and Emerging Markets. Her mission is to bridge the gap between medical innovation and patient accessibility, driven by a passion for developing therapies that truly resonate with patient needs and delivering outcomes that are meaningful to them.
Witnessing the significant access challenges faced by innovative medicines in reaching people in need prompted her to pivot into patient advocacy. She is now dedicated to addressing these barriers across the drug development lifecycle, collaborating with patients and those who care for them, physicians, access decision-makers and industry stakeholders to ensure that transformative therapies that are developed can reach those who need them most.
Anja is a Swiss qualified pharmacist with a Ph. D. in medicinal chemistry from ETH Zurich.
She started her career as a manager research and development at Fumapharm AG, a small Swiss Biotech company, where she coordinated CMC activities and pre-clinical research studies for an oral MS drug in late-stage development. Her role included management of multiple academic research collaborations as well as external suppliers.
Anja moved to Biogen after acquisition of Fumapharm, where she held various roles with increasing responsibility in CMC development and external manufacturing. She has been responsible for clinical and commercial supply of various products and supported multiple product launches across different modalities and product stages. In her last role at Biogen, she was heading the external manufacturing biologics technology platform and was leading a team of relationship managers for strategic CDMO accounts.
Most recently, Anja has worked at different start-up companies as head of CMC, responsible for all CMC and supply related aspects for pre-clinical oncology programs including antibody-drug conjugates, small molecules and gene therapy products. Setting up an external supplier network and contract laboratories, as well as managing relationships with alliance partners has been a key aspect of her work.
I have more than 15 years in a Leadership role in clinical operations and compliance combined with a strong educational background in pharmacy and specialization in clinical pharmacology. Currently I have a Senior Management role in compliance and risk management function. I have an excellent performance record and am motivated by leadership roles with a strong commercial impact.
Leyla is an epidemiologist with over 20 years of experience in the pharmaceutical industry. Her career includes leadership positions at GSK, Takeda, and Novartis in both clinical and epidemiology fields, covering various vaccines and drug development projects across Asia, Latin America, the USA, and Europe. With her profound understanding of the complexities within global healthcare landscapes, she has played a crucial role in utilizing real-world data to support the launch of more than 30 products, enhance market access, expand product labels, develop commercial strategies, and inform internal decision-making. In her current position at Novo Nordisk, she leads evidence generation efforts across multiple regions and therapeutic areas, leveraging digital technologies and AI-driven solutions to capture real-world data that provide insights into patient journeys and treatment effectiveness.
Thomas brings over 20 years of experience in digital innovation, with a decade dedicated to digital & health tech across clinical trial and commercial settings from both academia and the industry. He has collaborated with both emerging startups and established digital health companies, supporting over 20 markets in selecting and implementing digital health technologies. In addition to this role, Thomas actively advises and mentors startup companies through global accelerator programs and lectures MBA participants.
Amir Ahari is a Persian / Swiss national having lived and worked since 1988 in Germany and Switzerland. He gained his mechanical engineering, business administration and health economics and outcomes research education in various renowned institutions and brings across 20 years of professional work experience and 13 years in pharmaceutical manufacturing, contracting, market access and evidence generation operations.
Since 2018 he is co-leading the only global SMA disease patient registry and acts as global studies and alliances lead for registries and registry-based studies. He also has a new role within the Novartis Organization as global SME for Patient Registries. Father of a 9 ½ years old son, he speaks fluently 5 languages and enjoys in his private time playing basketball, golf, skiing and visiting live music events.
Andrew Park has spent more than a decade designing, deploying, and consulting on customer experience programs for global Fortune 1000 companies. Andrew provides strategic counsel to his clients, architecting and evolving their customer experience initiatives to deliver maximum business and relationship impact. In his current role as Head of Strategic Markets, he oversees the Go To Market, partnership, and customer experience initiatives for Suralink’s highest priority markets. He is CCXP certified, a recipient of CXPA CX Impact Award, the author of several white papers, an experienced speaker, and regularly contributes to public conversations about customer experience in forums like the Huffington Post, Inc, and Forbes.
